LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

被引：0

作者：

Yang, Wei ^{[1
]}

Burns, Colleen ^{[1
]}

Lindquist, Kevin ^{[2
]}

Dobkin, Julie ^{[1
]}

Shin, Hee Rae ^{[1
]}

Nguyen, Cindy ^{[1
]}

Huang, Xiaodong ^{[1
]}

Helms, Whitney ^{[3
]}

Arce, Nicholas ^{[2
]}

Mak, Yvonne ^{[2
]}

Au, Audrey ^{[1
]}

Abouzeid, Abraham ^{[4
]}

Witek, Marta ^{[4
]}

Leow, Ching Ching ^{[1
]}

Gong, Xueqian ^{[4
]}

Srinivasan, Mohan

Park, Joshua I. ^{[2
]}

Driscoll, Kyla ^{[1
]}

Hass, Andrew ^{[4
]}

Holmgaard, Rikke ^{[1
]}

Duramad, Omar ^{[2
]}

Bedard, Kristin ^{[2
]}

机构：

[1] LoxoLilly, New York, NY USA

[2] LoxoLilly, South San Francisco, CA USA

[3] LoxoLilly, Silver Spring, MD USA

[4] Eli Lilly & Co, Indianapolis, IN USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-200316

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2785 / 2786

页数：2

共 50 条

[41] A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies
Mazza, Irit Avivi
Barba, Pere
Yuda, Junichiro
Palomba, Maria Lia
Alderuccio, Juan Pablo
de Vriendt, Ciel
Corradini, Paolo
Lim, Francesca Lorraine Wei Inng
Zinzani, Pier Luigi
Jain, Nitin
Leonard, Jessica T.
Coulson, Michelle
Hassounah, Nadia
Yang, Xiaoling
Lu, Haihui
Lewandowski, Andrew
Polli, Joseph Ryan
Klopfenstein, Matthieu
Pastore, Alessandro
Brisou, Gabriel
BLOOD, 2023, 142
[42] IBI3001: A potentially first-in-class site-specifically conjugated B7H3/EGFR bispecific ADC for multiple solid tumors
Guan, Jian
Zhang, Xiao
Wu, Weiwei
Cao, Lei
Liao, Zhengguang
Zhu, Tianyu
Liu, Chentao
Zhou, Shuaixiang
Lu, Jia
Li, Ninghuan
Luo, Nana
Zhang, Ying
Dian, Kang
Chia, Tiong Sun
Chen, Bingliang
He, Kaijie
CANCER RESEARCH, 2024, 84 (07)
[43] Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies
Shah, Nirav N.
Krishnan, Amrita Y.
Shah, Nina D.
Burke, John M.
Melear, Jason M.
Spira, Alexander I.
Popplewell, Leslie L.
Andreadis, Charalambos B.
Chhabra, Saurabh
Sharman, Jeff P.
Kaufman, Jonathan L.
Cohen, Jonathon B.
Niesvizky, Ruben
Martin, Thomas G., III
Dilea, Clifford
Kuriakose, Jason
Matheny, Shannon L.
Leonard, John P.
Molina, Arturo
BLOOD, 2019, 134
[44] Pre-Clinical Characterization of T Cell-Dependent Bispecific Antibody Anti-CD79b/CD3 As a Potential Therapy for B Cell Malignancies
Sun, L. Laura
Chen, Xiaocheng
Chen, Yvonne
Dennis, Mark S.
Ellerman, Diego
Johnson, Clarissa
Mathieu, Mary
Oldendorp, Amy
Polson, Andrew G.
Reyes, Arthur
Stefanich, Eric
Wang, Hong
Wang, Peiyin
Zheng, Bing
Ebens, Allen J.
BLOOD, 2014, 124 (21)
[45] The First-In-Class Anti-AXLxCD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas
Polera, Nicoletta
Mancuso, Antonia
Riillo, Caterina
Caracciolo, Daniele
Signorelli, Stefania
Grillone, Katia
Ascrizzi, Serena
Hokanson, Craig A.
Conforti, Francesco
Staropoli, Nicoletta
Gervasi, Luigia
Di Martino, Maria Teresa
Arbitrio, Mariamena
Nistico, Giuseppe
Crea, Roberto
Tagliaferri, Pierosandro
Juli, Giada
Tassone, Pierfrancesco
CANCERS, 2023, 15 (06)
[46] First-in-Class PD-1/IL-2 Bispecific Antibody IBI363 In Patients with Advanced Non-Small Cell Lung Cancer in a Phase I Study
Zhou, J.
Xu, N.
Shan, J.
Wang, Y.
Fang, W.
Wang, H.
Pan, Y.
Chen, Y.
Liang, X.
Chu, Q.
Cui, J.
Sun, Y.
Fang, J.
Liu, X.
Li, N.
Long, S.
Chen, Y.
Zhao, L.
Wang, H.
Liang, T.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S97 - S97
[47] Bi20 a new trifunctional bispecific antibody (CD20xCD3) in the treatment of resistant B cell tumors: First clinical data.
Simoes, BP
Stanglmaier, M
Faltin, M
Ruf, P
Schmid, C
Bergmann, M
Humann, M
Wegner, H
Lang, N
Ledderose, G
Lindhofer, H
Kolb, HJ
BLOOD, 2003, 102 (11) : 297B - 297B
[48] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study
Zhang, Li
Ma, Yuxiang
Zhao, Yuanyuan
Fang, Wenfeng
Zhao, Hongyun
Huang, Yan
Yang, Yunpeng
Chen, Likun
Hou, Xue
Zou, Wen
Ding, Muran
Yu, Jing
Zhang, Suoyu
Wang, Junxian
Xiao, Sa
Wang, Hongwei
Zhu, Hai
Olivo, Martin Sebastian
Zhu, Yi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[49] Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer
Wang, Peiyin
Sun, Liping L.
Clark, Robyn
Hristopoulos, Maria
Chiu, Cecilia P. C.
Dillon, Michael
Lin, WeiYu
Lo, Amy A.
Chalsani, Sreedevi
Das Thakur, Meghna
Savill, Kristin M. Zimmerman
Rouge, Lionel
Lupardus, Patrick
Piskol, Robert
Husain, Bushra
Ellerman, Diego
Shivva, Vittal
Leong, Steven R.
Ovacik, Meric
Totpal, Klara
Wu, Yan
Spiess, Christoph
Lee, Genee
Leipold, Douglas D.
Polson, Andrew G.
MOLECULAR CANCER THERAPEUTICS, 2022, 21 (06) : 974 - 985
[50] Preliminary results of a first-in-human study on ESG206, a novel anti-BAFF-R monoclonal antibody, in relapsed or refractory B-cell malignancies
Song, Yuqin
Lin, Ningjing
Liu, Hui
Zhou, Qing
Xing, Xiaoyan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →